Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brachytherapy and bivalirudin evaluation study.

Pramod Kuchulakanti1, Roswitha Wolfram, Rebecca Torguson

  • 1Division of Cardiology, Department of Internal Medicine, Washington Hospital Center, Washington, DC 20010, USA.

American Heart Journal
|October 8, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of cardiovascular implantable electronic device leads post implant: ElectroPhysiology Predictable And SuStainable Implementation Of National Registries (EP PASSION).

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2022
Same author

Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial.

Lancet (London, England)·2020
Same author

Impact of Baseline Left Ventricular Diastolic Dysfunction in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

The American journal of cardiology·2019
Same author

Clinical conference proceedings of the 15th Biennial International Andreas Gruentzig Society Meeting held February 4 to 7, 2019 in Puerto Natales, Chile.

The Journal of invasive cardiology·2019
Same author

Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis following transcatheter aortic valve replacement.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2018
Same author

Comparison of coronary revascularization appropriateness for non-acute coronary syndrome cases under the 2017 update vs the 2012 appropriate use criteria.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2018

Bivalirudin is safe for percutaneous coronary intervention (PCI) with vascular brachytherapy (VBT) using beta radiation. However, its use with gamma radiation during PCI and VBT is not recommended due to increased thrombosis risk.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Thrombosis Management

Background:

  • Bivalirudin is a potential heparin alternative in percutaneous coronary intervention (PCI).
  • The safety and efficacy of bivalirudin in patients undergoing both PCI and vascular brachytherapy (VBT) remain unknown.
  • This study evaluates bivalirudin as a sole antithrombotic agent in PCI and VBT procedures.

Purpose of the Study:

  • To assess the safety and efficacy of bivalirudin.
  • To evaluate bivalirudin as a single antithrombotic agent.
  • To compare outcomes in patients undergoing PCI and VBT with beta vs. gamma radiation.

Main Methods:

  • 152 patients undergoing PCI and VBT were treated with bivalirudin.
  • Patients received either gamma (n=8) or beta radiation (n=144).

Related Experiment Videos

  • Bivalirudin was administered as a single agent throughout the procedures with specific dosing for beta and gamma radiation.

    • Main Results:

    • Acute procedural intracoronary thrombosis was significantly higher in the gamma radiation group (25%) compared to the beta radiation group (0.7%).
    • In-hospital and 30-day clinical outcomes, including mortality and myocardial infarction, were similar between groups.
    • Over 90% of patients received beta radiation, with similar baseline characteristics.

    Conclusions:

    • Bivalirudin can be safely used as a single antithrombotic agent during PCI and VBT with beta emitters.
    • The use of bivalirudin in PCI and VBT with gamma radiation is not advisable due to a higher incidence of acute procedural intracoronary thrombosis.
    • Further research may be needed to explore alternative strategies for patients requiring gamma radiation during PCI and VBT.